2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-N-{1-[4-(2-piperidin-4-yl-ethyl)-piperazine-1-carbonyl]-cyclopentyl}-benzenesulfonamide | 635697-34-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-N-{1-[4-(2-piperidin-4-yl-ethyl)-piperazine-1-carbonyl]-cyclopentyl}-benzenesulfonamide
• 英文别名: 2,4-dichloro-3-[(2,4-dimethylquinolin-8-yl)oxymethyl]-N-[1-[4-(2-piperidin-4-ylethyl)piperazine-1-carbonyl]cyclopentyl]benzenesulfonamide
• CAS: 635697-34-6
• 化学式: C₃₅H₄₅Cl₂N₅O₄S
• 分子量: 702.745
• InChiKey: KHIYBOHDGQYXDT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  47
• 可旋转键数：
  10
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  112
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• [EN] BASIC NON-PEPTIDE BRADYKININ ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THEREFROM<br/>[FR] ANTAGONISTES DE BRADYKININE NON PEPTIDIQUE DE BASE ET COMPOSITIONS PHARMACEUTIQUES A BASE DESDITS ANTAGONISTES
  申请人：MENARINI RICERCHE SPA

  公开号：WO2003103671A1

  公开（公告）日：2003-12-18

  Non-peptide compounds of formula (I) having activity as specific antagonists of bradykinin (BK) B2 receptor. The compounds are chemically characterized by the presence of an alpha, alpha-disubstituted amino acid at least one amino group, free or salified, or the corresponding ammonium quaternary salt. These BK receptor antagonists are a novel class of medicaments which can be used in all the disorders in which said receptors are involved.

  化学式为(I)的非肽类化合物具有作为布雷金肽(BK) B2受体特异性拮抗剂的活性。这些化合物在化学上的特征是至少有一个氨基团存在α，α-二取代氨基酸，自由或盐化，或相应的铵季铵盐。这些BK受体拮抗剂是一类新型药物，可用于所有涉及该受体的疾病中。
• Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom
  申请人：Calvani Federico

  公开号：US20060205712A1

  公开（公告）日：2006-09-14

  Non-peptide compounds of formula (I) having activity as specific antagonists of bradykinin (BK) B2 receptor. The compounds are chemically characterized by the presence of an alpha, alpha-disubstituted amino acid at least one amino group, free or salified, or the corresponding ammonium quaternary salt. These BK receptor antagonists are a novel class of medicaments which can be used in all the disorders in which said receptors are involved

  具有缓激肽（BK）B2 受体特异性拮抗剂活性的式（I）非肽化合物。这些化合物的化学特征是含有至少一个α-α-二取代氨基酸基团（游离的或盐化的）或相应的季铵盐。这些 BK 受体拮抗剂是一类新型药物，可用于治疗所有涉及上述受体的疾病。
• BASIC NON-PEPTIDE BRADYKININ ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THEREFROM
  申请人：Menarini Ricerche S.p.A.

  公开号：EP1513531A1

  公开（公告）日：2005-03-16
• US7491825B2
  申请人：——

  公开号：US7491825B2

  公开（公告）日：2009-02-17
• [EN] DIAGNOSIS, MONITORING, PROGNOSIS, PREVENTION AND TREATMENT OF ANEURYSMS<br/>[FR] DIAGNOSTIC, CONTRÔLE, PRONOSTIC, PRÉVENTION ET TRAITEMENT DES ANÉVRYSMES
  申请人：UNIV JAMES COOK

  公开号：WO2010127381A1

  公开（公告）日：2010-11-11

  The present invention relates generally to altering levels of components in the kallikrein-kinin system (KKS) to assist in preventing or treating aneurysms in an individual, and also to detecting the presence, determining the prognosis or monitoring the progression of an aneurysm by detecting aberrant expression of one or more genes in the kallikrein-kinin system (KKS). The invention also relates to methods for identifying agents that antagonise the KKS, and methods of producing agents comprising KKS antagonists for preventing or treating aneurysms.